ACAD News Alert Acadia Pharmaceuticals Inc (ACAD) 30.95 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Acadia Pharmaceuticals Inc (ACAD) 30.95 $ACAD

Today's Dead Cat Bounce Stock: ACADIA Pharmaceuticals (ACAD)
at The Street - Wed Dec 24, 8:57AM CST
Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "dead cat bounce" (down big yesterday but up big today) candidate
ACAD: 30.95 (+0.78)

4 Reasons I'm Adding Gilead To My Healthcare Holdings
Brian Nichols - at Seeking Alpha - Wed Dec 24, 6:18AM CST

JNJ: 104.59 (+0.31), ACAD: 30.95 (+0.78), GILD: 91.29 (+1.84), CLDX: 17.08 (-0.18)

ACADIA Pharmaceuticals (ACAD) Is Water-Logged And Getting Wetter Today
at The Street - Tue Dec 23, 11:40AM CST
Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
ACAD: 30.95 (+0.78)

Acadia Pharmaceuticals Shares Up 19.8% Since SmarTrend's Buy Recommendation (ACAD)
Comtex SmarTrend(R) - Wed Dec 17, 5:06PM CST
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on October 17th, 2014 at $26.29. In approximately 2 months, Acadia Pharmaceuticals has returned 19.84% as of today's recent price of $31.50.
ACAD: 30.95 (+0.78)

Cramer's Lightning Round - I Don't Want To Touch Fertilizer (12/12/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Sun Dec 14, 5:42AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Friday December 12. Bullish Calls: TrueCar (NASDAQ: TRUE ): "We like these companies. It is good. It is up on a spike, but I like it." Acadia...
MEMP: 14.46 (-0.31), SWX: 61.24 (+0.67), ACAD: 30.95 (+0.78), AGU: 95.91 (+0.20), TRUE: 23.50 (+0.31), PG: 93.14 (-0.15), TWTR: 37.61 (+0.04)

'Mad Money' Lightning Round: I Think You Should Buy, Buy, Buy Twitter
at The Street - Sat Dec 13, 5:00AM CST
Cramer likes Acadia Pharmaceuticals and TrueCar but is avoiding Agrium.
MEMP: 14.46 (-0.31), SWX: 61.24 (+0.67), ACAD: 30.95 (+0.78), AGU: 95.91 (+0.20), TRUE: 23.50 (+0.31), PG: 93.14 (-0.15), TWTR: 37.61 (+0.04)

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Dec 12, 7:38PM CST
Cramer will be watching company earnings while keeping an eye on oil futures to get a sense of where the market will move.
MMM: 166.96 (+0.09), SWX: 61.24 (+0.67), HON: 101.96 (-0.02), NKE: 96.29 (+0.32), CHTR: 167.46 (-0.31), BBRY: 10.67 (-0.13), XON: 26.19 (+0.67), RMTI: 8.41 (-0.07), KMX: 67.61 (-0.15), MEMP: 14.46 (-0.31), ACAD: 30.95 (+0.78), PAYX: 47.06 (-0.31), AGU: 95.91 (+0.20), TRUE: 23.50 (+0.31), LOW: 67.51 (-0.43), TWTR: 37.61 (+0.04), REGN: 400.12 (+6.07), JOY: 48.23 (+0.31), FDX: 176.42 (-0.52), LBRDA: 50.88 (-0.37), FINL: 22.79 (+0.17), ORCL: 46.23 (+0.22), DRI: 58.42 (-0.09), BAX: 74.45 (-0.04), RHT: 70.92 (+0.47), AGIO: 109.67 (+2.45), PAY: 37.55 (-0.83), PG: 93.14 (-0.15)

Biotech Equities Update - Biogen Idec, ACADIA Pharma, Halozyme Therapeutics, Neurocrine Biosciences, and Bluebird Bio
PR Newswire - Fri Dec 12, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Biogen Idec Inc. (NASDAQ: BIIB), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Halozyme Therapeutics Inc. (NASDAQ: HALO), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and Bluebird Bio Inc. (NASDAQ: BLUE). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, December 11, 2014, the NASDAQ Composite ended at 4,708.16, up 0.52%, the Dow Jones Industrial Average advanced 0.36%, to finish the day at 17,596.34, and the S&P 500 closed at 2,035.33, up 0.45%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 806.11, up 0.26%, with the index also advancing 8.67% in the previous three months. Register for your complimentary reports on these five stocks at:
BLUE: 88.76 (+3.23), BIIB: 340.89 (+5.13), ACAD: 30.95 (+0.78), NBIX: 21.33 (+0.09), HALO: 9.34 (+0.31)

Acadia Pharmaceuticals Has Returned 25.8% Since SmarTrend Recommendation (ACAD)
Comtex SmarTrend(R) - Wed Dec 10, 11:04AM CST
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on October 17th, 2014 at $26.29. In approximately 2 months, Acadia Pharmaceuticals has returned 25.78% as of today's recent price of $33.06.
ACAD: 30.95 (+0.78)

ACADIA Pharmaceuticals Presents Caregiver Burden Data at the International Congress of Non-Motor Dysfunctions in Parkinson's Disease and Related Disorders
Business Wire - Mon Dec 08, 8:00AM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the presentation of caregiver burden data from its Phase III program with NUPLAZID(TM) (pimavanserin) for Parkinson's disease psychosis (PDP) at the 10th Annual International Congress of Non-Motor Dysfunctions in Parkinson's Disease and Related Disorders held from December 5-7 in Nice, France. Data from an analysis of Phase III studies in patients with PDP showed that treatment with NUPLAZID reduced caregiver burden compared to PDP patients on placebo.
ACAD: 30.95 (+0.78)

Shares of ACAD Up 15.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Dec 03, 9:55AM CST
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on October 17th, 2014 at $26.29. In approximately 2 months, Acadia Pharmaceuticals has returned 15.85% as of today's recent price of $30.45.
ACAD: 30.95 (+0.78)

ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
Business Wire - Tue Nov 25, 8:01AM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the following investor conferences:
ACAD: 30.95 (+0.78)

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Tue Nov 25, 2:06AM CST

CXO: 99.86 (-0.04), CAM: 50.11 (-0.19), MDLZ: 37.63 (+0.05), MON: 120.97 (-1.70), DAL: 48.05 (+0.92), KSU: 122.50 (-0.80), CFX: 52.40 (-0.35), KORS: 75.30 (-0.01), RL: 184.35 (+0.70), PCP: 241.29 (+0.29), GOOG: 528.77 (-1.82), MOH: 53.39 (+0.61), PBR: 7.60 (-0.11), HLT: 26.21 (+0.11), DLTR: 69.86 (-0.20), LYB: 81.31 (-0.89), COF: 83.23 (-0.05), FOXA: 38.71 (-0.03), ABBV: 66.21 (+1.86), LOW: 67.51 (-0.43), REGN: 400.12 (+6.07), MA: 87.77 (+0.14), MU: 34.91 (-0.06), FB: 80.77 (+0.16), LNG: 71.64 (-0.12), NFX: 27.86 (-0.39), PXD: 150.84 (-1.60), ALXN: 181.96 (+3.09), ICPT: 151.49 (+5.85), CTSH: 54.26 (+0.04), ADSK: 60.99 (+0.34), DHI: 24.80 (-0.01), CCI: 79.05 (-0.13), ACT: 254.20 (-1.68), LBTYK: 49.10 (+0.05), MDT: 74.08 (+0.31), C: 54.54 (+0.12), ILMN: 186.22 (+2.72), AON: 96.52 (-0.15), ADBE: 74.74 (+0.36), MMC: 58.32 (-0.07), HUM: 144.38 (-0.31), AGN: 210.12 (+0.95), ACAD: 30.95 (+0.78), LBTYA: 50.76 (-0.02), GOOGL: 536.93 (-1.84), AAPL: 112.01 (-0.53), APD: 148.58 (unch), HRB: 33.72 (-0.08), GLNG: 36.67 (+1.15), BAC: 17.98 (+0.05), NFLX: 342.10 (+5.67), HCA: 74.89 (-0.11), BIDU: 230.98 (-2.18), DVA: 76.06 (+0.07), KITE: 51.96 (+0.45), MHK: 154.56 (-0.21), CP: 194.85 (-0.13), BABA: 105.95 (+0.43)

Schizophrenia Therapeutics Market 2018 - First-Generation and Second-Generation Antipsychotics Segments Analyzed at ReportsnReports.com
PRWeb - Mon Nov 24, 11:30PM CST
Schizophrenia is a condition in which people interpret reality abnormally. The symptoms of schizophrenia can be managed through medication and psychological therapy. Increase in aging population, increased incidences of schizophrenia and rising awareness about mental illnesses are some of the key factors which are propelling the growth of the global schizophrenia therapeutics market. Awareness about schizophrenia among physicians and patients is also going to be a major factor which will increase the demand of schizophrenia drugs in the market.
JNJ: 104.59 (+0.31), ABT: 45.70 (-0.02), ACAD: 30.95 (+0.78), PFE: 31.42 (-0.03), MRK: 57.46 (+0.25), AZN: 70.44 (+0.26), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), NVS: 93.91 (+0.66)

Acadia Pharmaceuticals Earnings Review: 14 Days after Announcement Shares Up 0.8% (ACAD)
Comtex SmarTrend(R) - Mon Nov 24, 8:44AM CST
14 days ago, on November 10th, 2014, Acadia Pharmaceuticals (NASDAQ:ACAD) reported its earnings. Analysts, on average, expected a loss of $0.22 per share on sales of $72.0 thousand. Acadia Pharmaceuticals actually reported a loss of $0.25 per share on sales of $15.0 thousand, missing EPS estimates by $0.03 and matching revenue estimates. Since the company's report, shares of Acadia Pharmaceuticals have risen from $28.21 to $28.43, representing a gain of 0.8% in the past 14 days.
ACAD: 30.95 (+0.78)

Are Central Banks Panicking?
Leo Kolivakis - Seeking Alpha - Fri Nov 21, 12:50PM CST
Koh Gui Qing and Jason Subler of Reuters report, China surprises with interest rate cut to spur growth : China cut interest rates unexpectedly on Friday, stepping up efforts to support the world's second-biggest economy as it heads towards its...
PGNX: 6.99 (-0.03), BCRX: 11.83 (+0.76), AVNR: 16.91 (+0.01), ACAD: 30.95 (+0.78), IDRA: 3.89 (+0.02), QQQ: 104.30 (+0.09), SGEN: 31.10 (-0.14), XBI: 182.62 (+3.44), TGTX: 16.03 (+0.33), IBB: 299.80 (+5.12), THLD: 2.93 (+0.01), IWM: 119.76 (-0.10), TWTR: 37.61 (+0.04), XOMA: 3.68 (+0.11)

Acadia Pharmaceuticals Earnings In Retrospect: Down 3.8% in the Last 7 Days (ACAD)
Comtex SmarTrend(R) - Mon Nov 17, 2:57PM CST
7 days ago, on November 10th, 2014, Acadia Pharmaceuticals (NASDAQ:ACAD) reported its earnings. Analysts, on average, expected a loss of $0.22 per share on sales of $72.0 thousand. Acadia Pharmaceuticals actually reported a loss of $0.25 per share on sales of $15.0 thousand, missing EPS estimates by $0.03 and matching revenue estimates. Shares of Acadia Pharmaceuticals have slipped from $28.21 to $27.14, representing a loss of 3.8%, since the company reported earnings 7 days ago.
ACAD: 30.95 (+0.78)

ACADIA Pharmaceuticals to Present at Jefferies 2014 Global Healthcare Conference on November 20, 2014
Business Wire - Thu Nov 13, 8:01AM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the Jefferies 2014 Global Healthcare Conference on Thursday, November 20, 2014, at 9:20 a.m. GMT in London.
ACAD: 30.95 (+0.78)

Watch for Acadia Pharmaceuticals to Potentially Rebound After Falling 2.52% Yesterday
Comtex SmarTrend(R) - Tue Nov 11, 4:44PM CST
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $26.57 to a high of $28.19. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $27.03 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ACAD: 30.95 (+0.78)

ACADIA Pharmaceuticals' (ACAD) CEO Uli Hacksell on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 8:51PM CST

ACAD: 30.95 (+0.78)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 97

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 78

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
Cloud Optical Demand Is Running Ahead of Supply in 2026

Updated Category News Views 51

Fiber capacity has become the awkward bottleneck nobody can wish away. Dell’Oro Group says the optical transport equipment market expanded 24% year over year in the third quarter of 2026, with large North American cloud providers doing the heavy lifting. More pointedly, optical vendor revenue tied to those cloud customers jumped 75%. That is not a gentle improvement in...

Continue Reading
Four Data Quality Champions Put Trust on the Board

Updated Category News Views 65

A single rotten customer record can gum up an entire operation faster than most executives care to admit. Bad data does not merely make a dashboard look silly; it can foul forecasts, duplicate work, misdirect automation, and leave an AI project confidently spouting nonsense. That is why Infotech's 2026 Data Quality Emotional Footprint report deserves a look, even if...

Continue Reading
GIGABYTE Pitches Local AI Agents to Enterprise Buyers

Updated Category News Views 72

Enterprise AI has reached the awkward stage where a slick chatbot demo no longer cuts it. GIGABYTE used its November 13 AI Partner Summit at the Pacific Palms Resort to make a more grounded pitch: companies need hardware and software setups that can put AI agents to work without casually tossing proprietary information into somebody else’s cloud. That is a sensible...

Continue Reading
E-Rate Risk and Data Center Rules Demand Attention

Updated Category News Views 71

America’s digital plumbing is getting squeezed at both ends: the public connections nobody notices until they fail, and the industrial-scale computing boom everybody suddenly wants built yesterday. Connected Nation’s two bonus podcast episodes from the Broadband Nation Expo in New Orleans put those pressures side by side, and it is a more useful pairing than it may...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 88

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
HVAC’s $383.6 Billion Shift Is About More Than Units

Updated Category News Views 163

Server racks are turning cooling gear into a front-row industrial story, and that deserves more attention than the usual sleepy talk about replacement air conditioners. Frost & Sullivan projects the global HVAC equipment market will reach $383.6 billion by 2031, growing at a 7.0% compound annual rate from 2025. That is a sizable market, sure, but the more interesting...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 130

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
Sprocket’s GigaOm Leap Puts PTaaS Claims Under Scrutiny

Updated Category News Views 44

Security vendors love a shiny quadrant, but this one deserves more than the usual polite golf clap. Sprocket Security moved from Challenger and Outperformer in GigaOm’s 2025 Penetration Testing as a Service assessment to a Leader in the version 5 report released in 2026. That is a meaningful jump in a category where buyers are tired of annual testing reports that go...

Continue Reading

Top 5 Most Recently Viewed Articles

DexCom Faces Class Action Lawsuit Over Securities Fraud Claims

Updated Category News Views 104

Overview of the Class Action Against DexCom, Inc. Investors in DexCom, Inc. are currently navigating important developments as a class action lawsuit has been filed. This legal action involves serious allegations of securities fraud against the company. Shareholders who have purchased DexCom securities may be affected, raising important questions about financial integrity...

Continue Reading
Amaroq Minerals Announces AGM Results and Future Directions

Updated Category News Views 209

Amaroq Minerals Ltd. Annual General Meeting Results Amaroq Minerals Ltd. is proud to share the results from its recent Annual General Meeting (AGM), reflecting a robust commitment from shareholders in shaping the future direction of the company. Held in a welcoming atmosphere, the event focused on critical decisions that underscore the corporation's strategic objectives...

Continue Reading
Explore the Theme of Connection and Creation at CIFF 2026

Updated Category News Views 254

Exciting New Developments at CIFF 2026 CIFF, the China International Furniture Fair, is gearing up for its 57th edition in March 2026. With a fresh theme, "CONNECT • CREATE", the event reflects the dynamic landscape of the furniture industry. The fair will facilitate exceptional connections within the furniture supply chain, including production, distribution, and...

Continue Reading
SpaceX's Starship to Showcase Advanced Starlink Technologies

Updated Category News Views 545

SpaceX's Latest Milestone in Satellite Technology Elon Musk's company, SpaceX, is gearing up for an exciting upcoming test flight of its Starship launch vehicle. The mission's highlight is the planned deployment of 10 model Starlink satellites, marking a significant step in demonstrating SpaceX's prowess in the satellite launch industry. The Innovative Starlink Satellites...

Continue Reading
DATAMYTE Introduces AI Efficiency in Mobile Inspections for APQP

Updated Category News Views 354

Transforming Quality Inspections with AI at DATAMYTE DATAMYTE, a leader in manufacturing technology, is truly reshaping the way inspections are conducted in the industry. By utilizing its innovative DIGITAL CLIPBOARD mobile platform alongside the powerful DATAMYTE GPT Artificial Intelligence System, the company is redefining the manual processes traditionally associated...

Continue Reading